Lilly's Cialis meets endpoints in Ph III study in men with both erectile dysfunction and BPH
US drug major Eli Lilly (NYSE: LLY) says that a pivotal Phase III study of its blockbuster erectile dysfunction drug Cialis (tadalafil) met its co-primary endpoints, significantly improving measures of both ED and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both conditions.
Just last week, the US Food and Drug Administration approved Cialis to treat the signs and symptoms of BPH, a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and ED, when the conditions occur simultaneously (The Pharma Letter October 7). Cialis was approved in 2003 for the treatment of ED, and last year generated sales of $1.7 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze